Effect of Reducing the Dose of Stavudine on Body Composition, Bone Density, and Markers of Mitochondrial Toxicity in HIV‐Infected Subjects: A Randomized, Controlled Study | Zendy

Grace A. McComsey | Zendy; Vincenzina Lo Re | Zendy; MaryAnn O’Riordan | Zendy; Ulrich A. Walker | Zendy; Dirk Lebrecht | Zendy; Elma D. Baron | Zendy; Karam Mounzer | Zendy; Ian Frank | Zendy

Open Access

Effect of Reducing the Dose of Stavudine on Body Composition, Bone Density, and Markers of Mitochondrial Toxicity in HIV‐Infected Subjects: A Randomized, Controlled Study

Author(s) -

Grace A. McComsey,

Vincenzina Lo Re,

MaryAnn O’Riordan,

Ulrich A. Walker,

Dirk Lebrecht,

Elma D. Baron,

Karam Mounzer,

Ian Frank

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/529384

Subject(s) - stavudine , medicine , mitochondrial toxicity , toxicity , bone density , randomized controlled trial , human immunodeficiency virus (hiv) , pharmacology , physiology , zidovudine , immunology , viral disease , osteoporosis

Stavudine is widely used in developing countries. Lipoatrophy and mitochondrial toxicity have been linked to stavudine use, but it is unclear whether switching to a lower dose can reduce these toxicities while maintaining human immunodeficiency virus (HIV) suppression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research